At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
RVMD Revolution Medicines, Inc.
Post-Mkt 08-26 16:25:11 EDT
215.44
+4.06
+1.92%
盘后215.07
-0.37-0.17%
16:24 EDT
High218.30Low198.91Vol3.50M
Open209.32D1 Closing211.38Amplitude9.17%
Mkt Cap46.18BTradable Cap39.64BTotal Shares214.34M
T/O742.69MT/O Rate1.90%Tradable Shares184.00M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Revolution Medicines CEO Mark A. Goldsmith Reports Disposal of Common Shares Worth $16.87 Million
Reuters  ·  08-26 18:52
Revolution Medicines CEO Mark A. Goldsmith Reports Disposal of Common Shares Worth $16.87 Million
Revolution Medicines Prices Metastatic Pancreatic Cancer Drug Rasonque at $39,800 a Month
MT Newswires Live  ·  02:20
Revolution Medicines Prices Metastatic Pancreatic Cancer Drug Rasonque at $39,800 a Month
Revolution Medicines to Charge $39,800 a Month for Pancreatic Cancer Drug, Bloomberg Reports
MT Newswires Live  ·  02:02
Revolution Medicines to Charge $39,800 a Month for Pancreatic Cancer Drug, Bloomberg Reports
Revolution Medicines - Rasonque is NOW Commercially Available in the U.S. at a Wholesale Acquisition Cost of $39,800 for a 30-Day Supply - Conf Call
THOMSON REUTERS  ·  01:56
Revolution Medicines - Rasonque is NOW Commercially Available in the U.S. at a Wholesale Acquisition Cost of $39,800 for a 30-Day Supply - Conf Call
Revolution Medicines Posts Investor Presentation on Rasonque FDA Approval
Reuters  ·  01:45
Revolution Medicines Posts Investor Presentation on Rasonque FDA Approval
Revolution Medicines prices Rasonque at $39,800 for 30-day supply
TIPRANKS  ·  01:45
Revolution Medicines prices Rasonque at $39,800 for 30-day supply
Revolution Medicines announces FDA approval of Rasonque in adults
TIPRANKS  ·  01:05
Revolution Medicines announces FDA approval of Rasonque in adults
Revolution Medicines, - Rasonque 300 Mg Once-Daily Oral Tablets NOW Available in the U.S.
THOMSON REUTERS  ·  00:59
Revolution Medicines, - Rasonque 300 Mg Once-Daily Oral Tablets NOW Available in the U.S.
U.S. FDA Approves Revolution Medicines’ Rasonque™ (Daraxonrasib), the First Broad Ras-Targeted Medicine in Metastatic Pancreatic Cancer
THOMSON REUTERS  ·  00:59
U.S. FDA Approves Revolution Medicines’ Rasonque™ (Daraxonrasib), the First Broad Ras-Targeted Medicine in Metastatic Pancreatic Cancer
U.S. FDA Approves Revolution Medicines’ RASONQUE™ (daraxonrasib), the First Broad RAS-Targeted Medicine in Metastatic Pancreatic Cancer
GlobeNewswire  ·  00:59
U.S. FDA Approves Revolution Medicines’ RASONQUE™ (daraxonrasib), the First Broad RAS-Targeted Medicine in Metastatic Pancreatic Cancer
FDA Approves Drug for Pancreatic Cancer in Incredible Moment for Deadly Disease
Dow Jones  ·  08-26 23:18
FDA Approves Drug for Pancreatic Cancer in Incredible Moment for Deadly Disease
Movement Alert｜Revolution Medicines, Inc. Falls 5.34% in Regular Trading, Trading at $200.13
Market Focus  ·  08-26 22:46
Movement Alert｜Revolution Medicines, Inc. Falls 5.34% in Regular Trading, Trading at $200.13
US FDA Approves Revolution Medicines' Pancreatic Cancer Drug
Reuters  ·  08-26 22:43
US FDA Approves Revolution Medicines' Pancreatic Cancer Drug
FDA Approves First in Class Targeted Therapy for Metastatic Pancreatic Cancer
THOMSON REUTERS  ·  08-26 22:38
FDA Approves First in Class Targeted Therapy for Metastatic Pancreatic Cancer
Revolution Medicines, Inc. : Bernstein Raises Target Price to $179 from $151
THOMSON REUTERS  ·  08-21
Revolution Medicines, Inc. : Bernstein Raises Target Price to $179 from $151
Revolution Medicines Advances RASolve 308 Lung Cancer Trial, Raising Long-Term Upside Potential for RVMD
TIPRANKS  ·  08-21
Revolution Medicines Advances RASolve 308 Lung Cancer Trial, Raising Long-Term Upside Potential for RVMD
Movement Alert｜Revolution Medicines, Inc. Rises 5.05% in Regular Trading, BeiGene RAS Inhibitor Collaboration Continues to Drive Momentum
Market Focus  ·  08-18
Movement Alert｜Revolution Medicines, Inc. Rises 5.05% in Regular Trading, BeiGene RAS Inhibitor Collaboration Continues to Drive Momentum
Cullinan Climbs as Lung Cancer Drug Meets Late-Stage Trial Goal
Reuters  ·  08-13
Cullinan Climbs as Lung Cancer Drug Meets Late-Stage Trial Goal
Propanc Biopharma Highlights Differentiated Proenzyme Therapy PRP as a Potential Therapy of Choice Against RAS-Driven Cancers
GlobeNewswire  ·  08-12
Propanc Biopharma Highlights Differentiated Proenzyme Therapy PRP as a Potential Therapy of Choice Against RAS-Driven Cancers
Revolution Medicines Price Target Raised to $231.00/Share from $210.00 by Truist Securities
Dow Jones  ·  08-12
Revolution Medicines Price Target Raised to $231.00/Share from $210.00 by Truist Securities

Introduction

Company Name.
Revolution Medicines, Inc.
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Revolution Medicines, Inc., a clinical-stage oncology company, developing novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline comprises RAS(ON) Inhibitors designed to suppress oncogenic variants of RAS proteins, and RAS Companion Inhibitors for use in combination treatment strategies. The company's RAS(ON) Inhibitors RMC-6236 (RASMULTI), RMC-6291 (RASG12C), and RMC-9805 (RASG12D) are in clinical development. Its additional RAS(ON) Inhibitors in its pipeline include RMC-5127 (G12V), RMC-0708 (Q61H), and RMC-8839 (G13C), which are in IND-enabling development, and additional compounds targeting other RAS variants. The company has a collaboration agreement with Sanofi for the research and development of SHP2 inhibitors, including RMC-4630. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.
Issue price:
--